Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The PERSEPHONE trial: 6 months and 12 months of trastuzumab in breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.08.18
Views: 712
Rating:

Prof Mariana Chavez-McGregor - University of Texas MD Anderson Cancer Center, Houston, USA

Prof Chavez-McGregor speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about the PERSEPHONE trial.

PERSEPHONE studies whether women with early breast cancer can safely have trastuzumab for 6 months instead of 12.

Prof Chavez-McGregor describes how the results are generally positive, but also touches upon the drawbacks of the study.
 

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation